Preferred Label : Cofetuzumab Pelidotin;
NCIt synonyms : ADC PF-06647020; Immunoglobulin G1, Anti-(human protein tyrosine kinase 7) (humanized Mus musculus
clone hu24 gamma-chain), Disulfide with humanized Mus musculus clone hu24 kappa-chain,
Dimer, Thioether with N-(((4-((N-(6-(2,5-Dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl)-L-valyl-N5-(aminocarbonyl)-L-ornithyl)amino)phenyl)methoxy)carbonyl)-2-methylalanyl-N-((1S,2R)-2-methoxy-4-((2S)-2-((1R,2R)-1-methoxy-2-methyl-3-oxo-3-(((1S)-2-phenyl-1-(2-thiazolyl)ethyl)amino)propyl)-1-pyrrolidinyl)-1-((1S)-1-methylpropyl)-4-oxobutyl)-N-methyl-L-valinamide; ADC PF-7020;
NCIt definition : An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody against
human inactive tyrosine-protein kinase 7 (PTK7) linked, via a cleavable valine-citrulline
linker, to an analog of the auristatin microtubule inhibitor dolastatin 10, auristatin-0101,
with potential antineoplastic activity. Upon administration, cofetuzumab pelidotin
targets and binds to PTK7 expressed on tumor cells. Upon binding, internalization
and cleavage, auristatin-0101 binds to tubulin and inhibits its polymerization, resulting
in G2/M phase arrest and apoptosis of PTK7-expressing tumor cells. PTK7, a tumor-associated
antigen (TAA), is overexpressed on a variety of cancer cells.;
UNII : 249EAP69MT;
CAS number : 1869937-48-3;
Molecule name : h6M24-vc0101; PF 7020; PF 06647020; PF-7020; PF-06647020;
NCI Metathesaurus CUI : CL474137;
Origin ID : C123828;
UMLS CUI : C5235383;
Currated CISMeF NLP mapping
- Semantic type(s)
- UMLS correspondences (same concept)
- concept_is_in_subset
- has_target
